Five Prime Therapeutics News Releases http://investor.fiveprime.com/ Five Prime Therapeutics News Releases en Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8 http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-announce-first-quarter-2019-financial SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2019-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2019 financial results on  Wed, 17 Apr 2019 19:56:00 -0400 Five Prime Therapeutics News Releases 11851 Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-present-cowen-and-company-39th-annual SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer Tue, 05 Mar 2019 18:05:00 -0500 Five Prime Therapeutics News Releases 11801 Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-reports-fourth-quarter-and-full-year Significant Pipeline Expansion and Strong Clinical Execution in 2018 Phase 3 FIGHT Registrational Trial in Gastric and GEJ Cancer Enrolling Phase 2 Cabiralizumab/ Opdivo ® (nivolumab) Trial in Pancreatic Cancer Enrolling Phase 1 Starts for FPA150, FPT155 and BMS-986258 Multiple Data Readouts in Tue, 26 Feb 2019 16:05:00 -0500 Five Prime Therapeutics News Releases 11726 Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150 http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-doses-first-patient-phase-1b-trial First-in-class antibody targeting B7-H4 Dual mechanism blocks a T cell checkpoint pathway and delivers potent antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that express B7-H4 B7-H4 is over-expressed on hard-to-treat solid tumors with low response to checkpoint inhibition Wed, 20 Feb 2019 20:05:00 -0500 Five Prime Therapeutics News Releases 11711 Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-announce-fourth-quarter-and-full-year-4 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 7, 2019-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2018 financial Thu, 07 Feb 2019 16:05:00 -0500 Five Prime Therapeutics News Releases 11646 Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-present-guggenheim-healthcare-talks-idea SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 4, 2019-- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer, Mon, 04 Feb 2019 17:05:00 -0500 Five Prime Therapeutics News Releases 11641 Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-presents-data-safety-lead-phase-3-fight SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 17, 2019-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled “Phase 1 Results from the Thu, 17 Jan 2019 14:05:00 -0500 Five Prime Therapeutics News Releases 11621 Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities http://investor.fiveprime.com/news-releases/news-release-details/five-prime-announces-restructuring-focus-clinical-development SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 15, 2019-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on Tue, 15 Jan 2019 16:05:00 -0500 Five Prime Therapeutics News Releases 11611 Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-announces-two-poster-presentations-0 Mon, 14 Jan 2019 21:13:00 -0500 Five Prime Therapeutics News Releases 11606 Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-present-37th-annual-jp-morgan-healthcare SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 12, 2018-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker , Chief Executive Officer, will Wed, 12 Dec 2018 16:05:00 -0500 Five Prime Therapeutics News Releases 11571